🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

120 results for “Accord” Clear

  1. TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN

    Cancer Prevention Pharma (Ireland) Limited

    Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.

    phase 2 small molecule active

    1 trial
  2. TREMELIMUMAB, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione, DURVALUMAB

    Fondazione Telethon ETS

    locally advanced cholangiocarcinoma

    phase 2 small molecule active

    1 trial
  3. Temozolomide Accord 180 mg hard capsules., Temozolomide Accord 250 mg hard capsules., Temozolomide Accord 5 mg hard capsules., Temozolomide SUN 5 mg hard capsules, Temozolomide Accord 20 mg hard capsules., Temozolomide SUN 180 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide Accord 100 mg hard capsules., Temozolomide SUN 140 mg hard capsules, Temozolomide Accord 140 mg hard capsules., Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 20 mg hard capsules

    Disc Medicine

    Diffuse Midline Glioma, H3K27-altered

    phase 2 small molecule active

    1 trial
  4. Temozolomide Accord 5 mg hard capsules., Temozolomide ratiopharm 20 mg, capsules, hard, Temozolomide ratiopharm 250 mg, capsules, hard, Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 180 mg hard capsules, Temozolomide Accord 140 mg hard capsules., TEMOZOLOMIDE VIATRIS 180 mg, gélule, Temozolomide ratiopharm 180 mg, capsules, hard, Temozolomide SUN 5 mg hard capsules, TEMOZOLOMIDE VIATRIS 140 mg, gélule, Temozolomide Accord 20 mg hard capsules, Temozolomide Accord 180 mg hard capsules., S95032/AG-88

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    IDH1-mutant Glioma, IDH2-mutant Glioma

    phase 2 small molecule active

    1 trial
  5. Tevimbra 100 mg concentrate for solution for infusion, Carboplatino Hikma 10 mg/ml soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial
  6. Vectibix 20 mg/ml concentrate for solution for infusion, VALPROIC ACID, VALPROIC ACID, Irinotecan Accord 20 mg/ml concentrato per soluzione perinfusione

    Fondazione Telethon ETS

    RAS/BRAF wild-type metastatic colorectal cancer

    phase 2 small molecule active

    1 trial
  7. Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial
  8. Cardiovascular safety assessment of Tanimilast in healthy volunteers

    Chiesi Farmaceutici S.p.A

    This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers.

    phase 1 other active

    1 trial
  9. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric cancer

    phase 1 small molecule active

    1 trial
  10. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial
  11. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial
  12. TRUQAP 200 mg film-coated tablets, Faslodex 250 mg solution for injection., TRUQAP 160 mg film-coated tablets, PACLITAXEL, IMFINZI 50 mg/mL concentrate for solution for infusion., Capecitabine Accord 500 mg film-coated tablets, Capecitabine Accord 150 mg film-coated tablets, DS-8201a, Arimidex® 1 mg film-coated tablets

    AstraZeneca AB

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial
  13. Cisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Locally advanced head and neck squamous cell carcinoma

    approved small molecule active

    1 trial
  14. Doxorubicin Accord 2 mg/ml koncentrat till infusionsvätska, lösning, Paclitaxel Accord 6 mg/ml koncentrat till infusionsvätska, lösning, Docetaxel Ebewe 10 mg/ml koncentrat till infusionsvätska, lösning, Epirubicin Accord 2 mg/ml injektions-/infusionsvätska, lösning, Sendoxan pulver till injektionsvätska, lösning

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Breast cancer female NOS

    approved small molecule active

    1 trial
  15. Fluconazol Accord 50 mg capsules, hard, Diflucan I.V. 2 mg/ml, oplossing voor infusie, Diflucan 100 mg, capsule, hard, Diflucan 10 mg/ml, poeder voor orale suspensie

    Disc Medicine

    Fungal infection

    approved small molecule active

    1 trial
  16. Methotrexate 2,5 mg film-coated tablets, Simponi 50 mg solution for injection in pre-filled syringe., Hydroxychloroquine sulfate 200mg film-coated Tablets, Cimzia 200 mg solution for injection in pre-filled syringe, Depo-Medrol 80 mg/2 ml Injektionssuspension, Leflunomide Aurobindo 20 mg compresse rivestite con film, Enbrel 50 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Sulfasalazine 500 mg Tablets, Jyseleca 200 mg film-coated tablets, Kenacort

    Disc Medicine

    Rheumatoid arthritis according to 2010 criteria

    approved small molecule active

    1 trial
  17. Pantoprazole Teva 40 mg maagsapresistente tabletten, Mycophenolate mofetil Sandoz 500 mg Film-coated Tablets, Mycophenolate Mofetil Accord 500 mg plėvele dengtos tabletės, CellCept 500 mg film-coated tablets

    Disc Medicine

    Post Transplantation Patients

    approved small molecule active

    1 trial
  18. Prednisona Pensa 5 mg comprimidos EFG, Simulect 20 mg powder for solution for injection or infusion, tacrolimus cinfa 1 mg cápsulas duras EFG, Micofenolato Mofetile Accord 250 mg capsule rigide, Metilprednisolona NORMON 40 mg polvo y disolvente para solución inyectable EFG, TIMOGLOBULINA 5 mg/ml, polvo para solución para perfusión

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Kidney Transplant

    approved small molecule active

    1 trial
  19. Sugammadex hameln 100 mg/ml oplossing voor injectie, Naloxon HCl Accord 0,4 mg/ml, oplossing voor injectie / infusie in een voorgevulde spuit, ANEXATE 0,5 mg/5 ml, solution injectable (I.V.), REMIMAZOLAM , Sufentanil Viatris 5 microgram/ml oplossing voor injectie, Esmeron 10 mg/ml, oplossing voor injectie

    Disc Medicine

    General anesthesia

    approved small molecule active

    1 trial
  20. TAGRISSO 80 mg film-coated tablets

    Fondazione Telethon ETS

    Patients with EGFR mutant NSCLC according to TP53 mutational status

    approved small molecule active

    1 trial
  21. TESTOGEL 50 mg gel transdérmico en sobres, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    approved small molecule active

    1 trial
  22. Urapidil Accord 5 mg/ml solución inyectable y para perfusión EFG, Trandate 5mg/ml Solution for Injection, Fenilefrina Altan 0,1 mg/ml solución inyectable y para perfusión.

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Acute Ischemic Stroke

    approved small molecule active

    1 trial
  23. XELJANZ 11 mg prolonged-release tablets

    Disc Medicine

    Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria

    approved small molecule active

    1 trial
  24. Ziagen 300 mg film-coated tablets, INTELENCE 200 mg tablets, Eviplera 200 mg/25 mg/245 mg film-coated tablets, EDURANT 25 mg film-coated tablets, Telzir 700 mg film-coated tablets, TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets, Delstrigo 100 mg/300 mg/245 mg film-coated tablets, Norvir 100 mg film-coated tablets, Ritonavir Accord 100 mg filmomhulde tabletten, Descovy 200 mg/10 mg film-coated tablets, REYATAZ 300 mg hard capsules, REKAMBYS 600 mg prolonged-release suspension for injection, Tivicay 50 mg

    Disc Medicine

    HIV-infected

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources